Baicalin provides protection against fluoxetine-induced hepatotoxicity by modulation of oxidative stress and inflammation

Figure 3 Effect of baicalin on serum enzymatic markers of liver function in fluoxetine-induced hepatotoxicity. A: Aspartate transaminase; B: Alanine transaminase; C: Alkaline phosphatase. Group 1: Control rats; group 2: Fluoxetine treated rats (10 mg/kg); group 3: Fluoxetine (10 mg/kg) + baicalin (50 mg/kg); group 4: Fluoxetine (10 mg/kg) + baicalin (100 mg/kg); group 5: Fluoxetine (10 mg/kg) + silymarin (100 mg/kg); group 6: Baicalin (100 mg/kg); group 7: Silymarin (100 mg/kg). Data represent mean ± SD, n = 6. ^aRepresents a significant difference compared with group 1, P < 0.05; ^brepresents a significant difference compared with group 2, P < 0.05; ^crepresents a significant difference compared with group 2, P < 0.005; ^drepresents a significant difference compared with group 2, P < 0.0001. AST: Aspartate transaminase; ALT: Alanine transaminase; ALP: Alkaline phosphatase.